Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Advances in Therapy|February 24, 2024
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple MyelomaHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
The Lancet. Haematology|March 28, 2020
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trialMaria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et al.
The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Pageof 6